

## Supporting Information

### **Designing an ECM-inspired supramolecular scaffold by utilizing the interactions between minimalistic neuroactive peptide and heparin**

Pooja Sharma<sup>a</sup>, Sangita Roy<sup>a\*</sup>

<sup>a</sup>Institute of Nano Science and Technology (INST), Sector 81, Knowledge City, Mohali,  
Punjab, India

## Table of contents:







1. **Table S1.** Minimum gelation concentration (MGC) and optical images of hydrogels formed after mixing Tc peptide and heparin at different ratio.
2. **Table S2.** Optical images of hydrogels formed after mixing Tc peptide and heparin at 10 mg/mL concentration of peptide.
3. **Figure S1.** Zeta potential measurement of the combined hydrogels near physiological pH.
4. **Figure S2.** Spectra representing the variation in HT with wavelength for Tc and heparin combined hydrogels at 10 mg/mL concentration.
5. **Figure S3.** CD and HT spectra of Tc-heparin combined hydrogels at 5mg/mL concentration.
6. **Figure S4.** Fluorescence microscopic images of hydrogels after ThT binding
7. **Figure S5.** Variation in Congo red spectra upon binding to Tc-heparin combined hydrogel.
8. **Figure S6.** Time dependent AFM images of the combined hydrogels.
9. **Figure S7.** Thixotropic studies of Tc-Heparin combined hydrogels at their differential mixing ratio.
10. **Figure S8.** Evaluation of the force required to inject the pre-formed hydrogel through 18 G needle.
11. **Figure S9.** Thermal annealing study of the hydrogel scaffolds.
12. **Figure S10.** Cell culture images of C6 cells showing the elongated morphology of adhered cells after 48 hours of treatment. Scale bar is 200  $\mu\text{m}$
13. **Figure S11.** Assessment of cytotoxicity of peptide and combined hydrogels towards SH-SY5Y in the oligomeric state at different mixing ratios.
14. **Figure S12.** Cell culture images of 1929 cells showing the elongated morphology of adhered cells after 48 hours of treatment. Scale bar is 200  $\mu\text{m}$ .
15. **Figure S13.** Quantification of cellular density from confocal images of C6 cells after 5 days of cell seeding.
16. **Figure S14.** Assessment of cellular adhesion and proliferation of SH-SY5Y cells on 2-D matrix of hydrogels by Live/Dead staining.
17. **Figure S15.** Assessment of cellular adhesion and proliferation of L929 cells on 2-D matrix of hydrogels by Live/Dead staining.

18. **Figure S16.** Quantification of cellular adhesion and proliferation on 2-D matrix of hydrogels by alamar blue assay on human neuroblastoma cell line, SH-SY5Y.
19. **Figure S17.** Immunostaining of human neuroblastoma cell line, SH-SY5Y with neural marker protein  $\beta$ -III tubulin after 5 days of 2-D cell culture at 10 mg/mL concentration without  $\beta$ -III tubulin primary antibody.
20. **Figure S18.** Immunostaining of human neuroblastoma cell line, SH-SY5Y with neural marker protein  $\beta$ -III tubulin after 5 days of 2-D cell culture at 10 mg/mL concentration.
21. **Figure S19.** Immunostaining of rat glioma cell line, C6 with neural marker protein  $\beta$ -III tubulin after 5 days of 2-D cell culture at 10 mg/mL concentration.
22. **Figure S20.** Quantification of (a) cells spreading area and (b) cell shape index of rat glioma cell line, C6 on uncoated coverslip and combined hydrogels.
23. **Figure S21.** Cytoskeleton staining mouse fibroblast cell line, L929 after 5 days of 2-D cell culture.
24. **Figure S22.** Quantification of (a) cells spreading area and (b) cell shape index of mouse fibroblast cell line, L929 on uncoated coverslip and combined hydrogels.
25. **Figure S23.** Z-stack rendering images of the SH-SY5Y cells after live/dead staining in the 3-D cell culture conditions.
26. **Figure S24.** Assessment of cellular migration of C6 cells in the presence of hydrogel treatment.
27. **Figure S25.** Assessment of cellular migration of SH-SY5Y cells in the presence of hydrogel treatment.
28. **Figure S26.** Assessment of cellular migration of L929 cells in the presence of hydrogel treatment.
29. **Figure S27.** Microscopic images showing the cellular morphology of Raw cells after hydrogel treatment.

**Table S1.** Minimum gelation concentration (MGC) and optical images of hydrogels formed by co-assembly of heparin and Tc peptide at different (w/w) ratio.

<b>Tc (mg/mL)</b>	<b>Heparin (mg/mL)</b>	<b>Ratio Tc: heparin</b>	<b>Gelation pH</b>	<b>Status after 24 hrs</b>	<b>Images</b>
2.5	2.5	1:1	7.0	Sol	
5 (MGC of composite hydrogel)	5	1:1	7.0	Gel	
5	2.5	2:1	7.0	Gel	
5	1	5:1	7.0	Gel	
5	10	1:2	7.0	Gel	
5	0	Control peptide	7.0	Sol	

**Table S2.** Optical images of hydrogels formed by mixing heparin and Tc peptide at 10 mg/mL concentration of peptide.

<b>Tc (mg/mL)</b>	<b>Heparin (mg/mL)</b>	<b>Ratio Tc: heparin</b>	<b>Gelation pH</b>	<b>Status after 24 hrs</b>	<b>Images</b>
10	0	Control peptide	7.0	Gel	
10	10	1:1	7.0	Gel	
10	5	2:1	7.0	Gel	
10	2	5:1	7.0	Gel	
10	20	1:2	7.0	Gel	
0	10	Control heparin	7.0	Sol	






Figure S1. Zeta potential measurement of the combined hydrogels near physiological pH.




**Figure S2.** Spectra representing the variation in HT with wavelength for Tc and heparin combined hydrogels at 10 mg/mL concentration.



**Figure S3.** (a) CD spectra of Tc-heparin combined hydrogels at 5mg/mL concentration showing the variation in the supramolecular organization of Tc in the presence of heparin. (b) Spectra representing the variation in HT with wavelength for Tc and heparin combined hydrogels at 5 mg/mL concentration.





**Figure S4.** Fluorescence microscopic images of (a) control ThT solution, (b) Heparin, (c) 1:1 combined gel, (d) 2:1 combined gel, (e) 5:1 combined gel, (f) 1:2 combined gel showing binding of hydrogels with ThT. Scale bar is 200  $\mu\text{m}$ .







Figure S5. Variation in Congo red spectra upon binding to Tc-heparin combined hydrogel.




**Figure S6.** Time dependent AFM images of the combined hydrogels showing the nucleation and growth of the supramolecular nanofibers to form hydrogel scaffold. AFM images of (a-f) 1:1 combined gel, (g-l) 2:1 combined gel, (m-r) 5:1 combined gel and (s-x) 1:2 combined gel. Scale bar is 500 nm.




**Figure S7.** Thixotropic studies of Heparin-Tc co-assembled hydrogels showing mechanoresponsive behaviour. Variation in storage modulus ( $G'$ ) and loss modulus ( $G''$ ) of the (a) 2:1 combined gel and (b) 5:1 combined gel upon application of step strain cycle.




**Figure S8.** (a) Customized axial compression testing device. (b) The force required to inject the pre-formed hydrogel through 18 G needle from a 2.5 cc syringe at an injection rate of 150  $\mu\text{l/s}$ . Data is represented as force vs time. Inset images show the syringe carrying the hydrogel material attached to custom-made step-up used in the experiment.



**Figure S9.** Thermal annealing study of the hydrogel scaffolds at 10 mg/mL concentration. AFM images of (a) 1:1 combined gel, (b) 2:1 combined gel, (c) 5:1 combined gel, (d) 1:2 combined gel, (e) Tc hydrogel after thermal annealing, (f) Frequency sweep analysis of the thermally annealed hydrogels showing the variation in  $G'$  (Pa) after heat treatment. Scale bar is 500 nm.




**Figure S10.** Cell culture images of C6 cells showing the elongated morphology of adhered cells after 48 hours of treatment (1000  $\mu\text{g}/\text{mL}$ ). Scale bar is 200  $\mu\text{m}$ .




**Figure S11.** Assessment of cytotoxicity of peptide and combined hydrogels in the oligomeric state at different mixing ratios. (a) Evaluation of cytotoxicity of hydrogel treatment on SH-SY5Y (Human neuroblastoma cell line). Cell culture images showing the morphology of adhered cells after 48 hours of treatment (1000 µg/mL), (b) Heparin, (c) 1:1 combined gel, (d) 2:1 combined gel, (e) 5:1 combined gel, (f) 1:2 combined gel, (g) Tc hydrogel. Scale bar is 200 µm.







**Figure S12.** Cell culture images of 1929 cells showing the elongated morphology of adhered cells after 48 hours of treatment (1000  $\mu\text{g}/\text{mL}$ ) . Scale bar is 200  $\mu\text{m}$ .




**Figure S13.** Quantification of cellular density from confocal images of C6 cells after 5 days of cell seeding.




**Figure S14.** Assessment of cellular adhesion and proliferation on 2-D matrix of hydrogels by Live/Dead staining at 10 mg/mL concentration. Confocal laser scanning microscopic images of human neuroblastoma cell line, SH-SY5Y (a-c) control coverslip, (d-f) Heparin, (g-i) 1:1 combined gel, (j-l) 2:1 combined gel, (m-o) 5:1 combined gel, (p-r) 1:2 combined gel and (s-u) Tc peptide gel. Scale bar is 100 μm.




**Figure S15.** Assessment of cellular adhesion and proliferation on 2-D matrix of hydrogels by Live/Dead staining at 10 mg/mL concentration. Confocal laser scanning microscopic images of mouse fibroblast cell line, L929 (a-c) control coverslip, (d-f) Heparin, (g-i) 1:1 combined gel, (j-l) 2:1 combined gel, (m-o) 5:1 combined gel, (p-r) 1:2 combined gel and (s-u) Tc peptide gel. Scale bar is 100 μm.




**Figure S16.** Quantification of cellular adhesion and proliferation on 2-D matrix of hydrogels by alamar blue assay on human neuroblastoma cell line, SH-SY5Y at 10 mg/mL concentration.



**Figure S17.** Immunostaining of human neuroblastoma cell line, SH-SY5Y with neural marker protein  $\beta$ -III tubulin after 5 days of 2-D cell culture at 10 mg/mL concentration without  $\beta$ -III tubulin primary antibody. CLSM images of cells after staining (a) control coverslip, (b) Heparin, (c) 1:1 combined gel, (d) 2:1 combined gel, (e) 5:1 combined gel, (f) 1:2 combined gel and (g) Tc peptide gel. Scale bar is 10  $\mu$ m.




**Figure S18.** Immunostaining of human neuroblastoma cell line, SH-SY5Y with neural marker protein  $\beta$ -III tubulin after 5 days of 2-D cell culture at 10 mg/mL concentration. CLSM images of cells after staining (a-c) control coverslip, (d-f) Heparin, (g-i) 1:1 combined gel, (j-l) 2:1 combined gel, (m-o) 5:1 combined gel, (p-r) 1:2 combined gel and (s-u) Tc peptide gel. Scale bar is 10  $\mu$ m.




**Figure S19.** Immunostaining of rat glioma cell line, C6 with neural marker protein  $\beta$ -III tubulin after 5 days of 2-D cell culture at 10 mg/mL concentration. CLSM images of cells after staining (a-c) control coverslip, (d-f) Heparin, (g-i) 1:1 combined gel, (j-l) 2:1 combined gel, (m-o) 5:1 combined gel, (p-r) 1:2 combined gel and (s-u) Tc peptide gel. Scale bar is 10  $\mu$ m.







**Figure S20.** Quantification of (a) cells spreading area and (b) cell shape index of rat glioma cell line, C6 on uncoated coverslip and combined hydrogels. Data are represented as mean  $\pm$  SD. “ns” stands for nonsignificant difference (one-way ANOVA, Bonferroni’s multiple comparisons tests)




**Figure S21.** Cytoskeleton staining mouse fibroblast cell line, L929 after 5 days of 2-D cell culture at 10 mg/mL concentration. CLSM images of cells after staining (a-c) control coverslip, (d-f) Heparin, (g-i) 1:1 combined gel, (j-l) 2:1 combined gel, (m-o) 5:1 combined gel, (p-r) 1:2 combined gel and (s-u) Tc peptide hydrogel. Scale bar is 10  $\mu\text{m}$ .




**Figure S22.** Quantification of (a) cells spreading area and (b) cell shape index of mouse fibroblast cell line, L929 on uncoated coverslip and combined hydrogels. Data are represented as mean  $\pm$  SD. “ns” stands for nonsignificant difference (one-way ANOVA, Bonferroni’s multiple comparisons tests)




**Figure S23.** Z-stack rendering images of the SH-SY5Y cells after live/dead staining in the 3-D cell culture conditions in case of (a) Matrigel, (b) 1:1 combined gel, (c) 2:1 combined gel, (d) 5:1 combined gel, (e) 1:2 combined gel and (f) Tc peptide gel.




**Figure S24.** Assessment of cellular migration of C6 cells in the presence hydrogel treatment (1000  $\mu\text{g}/\text{mL}$ ). Scratch closure in (a,h,o) control, (b,i,p) Heparin (c,j,q) 1:1 combined gel, (d,k,r) 2:1 combined gel, (e,l,s) 5:1 combined gel, (f, m, t) 1:2 combined gel and (g,n,u) Tc peptide gel at 0, 12 and 24 hours respectively. Scale bar is 200  $\mu\text{m}$ .



**Figure S25.** Assessment of cellular migration of SH-SY5Y cells in the presence hydrogel treatment (1000  $\mu\text{g/mL}$ ). Scratch closure in (a,h,o) control, (b,i,p) Heparin (c,j,q) 1:1 combined gel, (d,k,r) 2:1 combined gel, (e,l,s) 5:1 combined gel, (f, m, t) 1:2 combined gel and (g,n,u) Tc peptide gel at 0, 12 and 24 hours respectively. Scale bar is 200  $\mu\text{m}$ .



**Figure S26.** Assessment of cellular migration of L929 cells in the presence hydrogel treatment (1000  $\mu\text{g/mL}$ ). Scratch closure in (a,h,o) control, (b,i,p) Heparin (c,j,q) 1:1 combined gel, (d,k,r) 2:1 combined gel, (e,l,s) 5:1 combined gel, (f, m, t) 1:2 combined gel and (g,n,u) Tc peptide gel at 0, 12 and 24 hours respectively. Scale bar is 200  $\mu\text{m}$ .



**Figure S27.** Microscopic Raw cell images showing the changes in cellular morphology on hydrogel at 10 mg/ml concentration. Optical images of the Raw cells after culturing on (a) control (no treatment), in the presence of (b) Heparin, (c) 1:1 combined gel, (d) 2:1 combined gel, (e) 5:1 combined gel, (f) 1:2 combined gel, (g) Tc peptide gel and (h) LPS (10  $\mu\text{g}/\text{mL}$ ).